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Abstract Heterozygous GATA-2 germline mutations are as-
sociated with overlapping clinical manifestations termed
GATA-2 deficiency, characterized by immunodeficiency and
predisposition to myelodysplastic syndrome (MDS) and acute
myeloid leukemia (AML). However, there is considerable
clinical heterogeneity among patients, and the molecular basis
for the evolution of immunodeficiency into MDS/AML re-
mains unknown. Thus, we conducted whole-genome se-
quencing on a patient with a germline GATA-2 heterozygous
mutation (c. 988 C > T; p. R330X), who had a history
suggestive of immunodeficiency and evolved into MDS/
AML. Analysis was conducted with DNA samples from
leukocytes for immunodeficiency, bone marrow mononuclear
cells for MDS and bone marrow-derived mesenchymal stem
cells. Whereas we did not identify a candidate genomic dele-
tion that may contribute to the evolution into MDS, a total of
280 MDS-specific nonsynonymous single nucleotide variants
were identified. By narrowing downwith the single nucleotide
polymorphism database, the functional missense database,
and NCBI information, we finally identified three candidate
mutations for EZH2, HECW2 and GATA-1, which may con-
tribute to the evolution of the disease.
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Introduction
GATA-2 is a zinc finger transcription factor that plays crucial
roles in hematopoiesis, as well as vascular, lymphatic, and
neural development [1]. Recently, heterozygous GATA-2
germline mutations, both inherited and de novo, were reported
to cause three overlapping clinical entities, characterized by a
predisposition to myelodysplastic syndrome (MDS) and acute
myeloid leukemia (AML): (1) familial MDS/AML, (2)
Emberger syndrome and (3) an immunodeficiency termed
monocytopenia characterized by mycobacterium avium com-
plex (MonoMAC)/dendritic cell, monocyte, B- and NK-
lymphoid deficiency (DCML) [2–4]. All these conditions
are generally named “GATA-2 deficiency” syndrome.
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Nearly half of the individuals presenting with GATA-2
mutations will eventually develop MDS/AML, associated
with fibrosis and megakaryocyte dysplasia. In contrast, many
patients gradually develop DCML before MDS/AML, initial-
ly detected as mild chronic neutropenia, monocytopenia and/
or NK deficiency [2–4]. Therefore, there is considerable clin-
ical heterogeneity among patients with GATA-2 deficiency,
although all these conditions predominantly affect the hema-
tologic and immune systems. In addition, the rate of evolution
of the disease into MDS/AML appears to be rapid, with
varying MDS and AML phenotypes and variable cytogenetic
abnormalities [5, 6]. Therefore, secondary genetic events may
explain the clinical heterogeneity among cases of GATA-2
deficiency. In this regard, the most commonly associated
cytogenetic finding is monosomy 7 and additional acquired
mutations, such as those in ASXL1 [6]. However, the molec-
ular basis for the evolution of GATA-2 deficiency into MDS/
AML has not been elucidated, which affects our ability of
early detection and treatment of the disease.
Whole-genome sequencing has several advantages over
candidate gene sequencing. It provides a comprehensive and
nonbiased approach to mutation detection. More importantly,
whole-genome paired-end sequencing is able to detect struc-
tural variants (SV; e.g., deletions, amplifications, inversions
and translocations). Therefore, to investigate the genetic
changes associated with the evolution of GATA-2 deficiency
into MDS/AML, we performed whole-genome sequencing of
MDS sample, which was compared with matched samples
from nail, leukocyte at immunodeficiency, and bone marrow-
derived mesenchymal stem cells (BM-MSCs).
Patient and methods
Study design and clinical samples
All clinical samples were obtained from a single patient re-
ferred to our department for pancytopenia and emergence of
myeloblasts in the peripheral blood. They included nails,
peripheral leukocytes at immunodeficiency (MonoMAC),
and bone marrow mononuclear cells for MDS (MDS). The
patient signed an informed consent before sample collection,
and all ethical considerations were followed according to the
Declaration of Helsinki. This study was approved by the
ethical committee of the Tohoku University Graduate School
of Medicine.
Cell culture
Cells were grown in a humidified incubator at 37 °C with 5 %
carbon dioxide. Human K562 erythroleukemia cell lines were
maintained in Roswell Park Memorial Institute (RPMI-1640)
medium containing 10 % fetal bovine serum (Biowest) and
1 % penicillin–streptomycin (Sigma). PLAT-GP Packaging
Cell Lines (Cell Biolabs) was maintained in Dulbecco’s mod-
ified Eagle medium (DMEM) containing 10 % fetal bovine
serum (Biowest) and 1 % penicillin–streptomycin (Sigma).
Gene transfer and vectors
GATA-2 mRNA was cloned into pBABE-puro vector
(Addgene Plasmid 1764) [7], and a single mutation was
introduced with QuikChange Site-Directed Mutagenesis Kit
(Agilent). The retroviral vector encoding human GATA-2 and
the env (envelope glycoprotein) gene from the vesicular sto-
matitis virus (VSV-G) were co-transfected into PLAT-GP cells
with FuGene HD (Promega). Seventy-two hours after trans-
fection, the viral supernatant was used for infection. After spin
infection into CD34-positive cells at 3,400 rpm for 2 h, the
cells were cultured containing 1 μg/mL Puromycin (Sigma)
for the selection of the transduced cells.
Quantitative ChIP analysis
Real-time-PCR-based quantitative chromatin immunoprecip-
itation (ChIP) analysis was conducted essentially as described
[8]. Cells were crosslinked with 1 % formaldehyde for 10 min
at room temperature. The nuclei lysate was sonicated to re-
duce DNA length using Sonifier (Branson). The protein-DNA
complexes were immunoprecipitated by specific antibody and
Protein A Sepharose (Sigma). Immunoprecipitated DNA frag-
ments were quantified by real-time PCR to amplify regions of
75–150 bp overlapping with the appropriate motif. Product
was measured by SYBR Green fluorescence in 20-μL reac-
tions, and the amount of product was determined relative to a
standard curve generated from titration of input chromatin.
Analysis of post-amplification dissociation curves showed
that primer pairs generated single products.
Primers
Primers used in the study were listed in Table 1.
Western blot analysis
Whole cell extracts were prepared by boiling cells for 10 min
in SDS sample buffer [25 mM Tris (pH 6.8), 2 % β-
mercaptoethanol, 3 % SDS, 0.1 % bromophenol blue, 5 %
glycerol] at 1×107 cells/mL. Extracts from 1 to 2×105 cells
were resolved by SDS-PAGE and transferred to Hybond-P
(GE Healthcare). The proteins were measured by semi-
quantitatively with ECL-Plus (GE Healthcare) and CL-X
PosureTM Film (Thermo Scientific).
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Antibodies
Antibodies to GATA-2 (H-116) and Actin (I-19) were obtain-
ed from Santa Cruz Biotechnology. Control rabbit IgG was
obtained from Abcam. Phycoerythrin (PE)-labeled human
CD29, PE-labeled human CD34, fluorescein isothiocyanate
(FITC)-labeled mouse/human CD44, FITC-labeled human
CD45, FITC-labeled human CD90 antibodies were purchased
from BD Biosciences.
The anti-GATA-2 antibody (H-116) recognizes amino acid
residues 120–235 of human GATA-2.
Flow cytometry (FACS)
The cells collected from culture were washed twice with
phosphate-buffered saline (PBS; Sigma). The cells were then
incubated with PE- and FITC-labeled antibodies, washed
twice with PBS, and analyzed using FACSAria II (Beckton,
Dickinson). The collected data were processed with FlowJo
software (http://www.flowjo.com/).
Establishment of BM-MSCs
To establish BM-MSCs, bone marrow mononuclear cells
from the patient were cultured in DMEM (Life Technologies)
supplemented with 20 % fetal bovine serum (Life Technolo-
gies), 10 ng/mL basic fibroblast growth factor (PeproTech),
10 mM HEPES (Life Technologies), and 100 μg/mL
penicillin/streptomycin, as previously described [9]. To in-
duce differentiation into osteroblasts and adipocytes, the
hMSC Mesenchymal Stem Cell Differentiation Medium
(Lonza) for osteogenic and adipogenic, respectively, was
used. Osteogenic cell layers were positive for Alkaline Phos-
phatase staining, and typical adipocytes contained oil drops
that were stained with Oil Red O.
Genome analysis
To identify MDS-specific genome alterations, whole-genome
sequencing was conducted on MonoMAC, MDS and BM-
MSCs (Fig. 1). Genomic DNAwas extracted with the DNeasy
Blood & Tissue Kit (QIAGEN) or ISOHAIR (NIPPON
GENE). For whole-genome sequencing, the DNA samples
were amplified with the REPLI-g Midi Kit (QIAGEN). Se-
quencing libraries were prepared from 1 μg of the amplified
DNA according to the TruSeq DNA Sample Prep Guide
(Illumina). The libraries were sequenced on an Illumina HiSeq
2000 with HiSeq control software (HCS) version 1.5 and
Real-Time Analysis (RTA) software version 1.13. After se-
quencing, reads were mapped to the human reference genome
(GRCh37/hg19) with decoy sequences (hs37d5) using BWA
[10] with the default options. Then, variant calling was con-
ducted using the GATK Unified Genotyper [11].
Sanger sequence-based validation analysis was conducted
with all samples, including the nail sample, using an ABI
3730xl DNA analyzer and the ABI BigDye Terminator Cycle
Sequencing Kit (Applied Biosystems). The validation analy-




In September 2010, a 35-year-old man was referred to our
department due to pancytopenia and emergence of myelo-
blasts in the peripheral blood. Peripheral blood count revealed
a white blood cell count of 1.2×109/L, with 79 % neutrophils,
16 % lymphocytes, 1 % eosinophils, 1 % atypical lympho-
cytes, and 3 % myeloblasts. The hemoglobin level was 9.8 g/
dl, and the platelet count was 27×109/L. Bone marrow anal-
ysis indicated a total nucleated cell count of 2.2×1010/L, with
dysplastic morphological changes in all lineages. The bone
Table 1 Oligonucleotide primers
Designation Forward and reverse sequences(5′-3′)
Primers used for GATA-2 sequencing
GATA-2 exon 2 GTTTTGAGCCTTGGGCTTT
CAATTTTTCAGCAGCTCGATT
GATA-2 exon 3 GGAGTCGTGATCTCAATGTCTG
ATCTGCTGGGGGCTATTAGAG
GATA-2 exon 4 ACTCCCTCCCGAGAACTTG
CGTCTGCATTTGAAGGAGTTT
GATA-2 exon 5 GAGATTTAGCCCTCCTTGACTG
AGCACAAAGCGCAGAGGT
GATA-2 exon 6 GAAGGTCGGGCACAATTC
ACAGGTGCCATGTGTCCA







Primers used for quantitative ChIP
GATA-2 −2.4 kb GTGGAGCTCTAGGGTACCATTT
TGAGGACACCTCATTAGAGCAG
GATA-2 −3.5 kb GTCCGGGGTAATTTTTCATCT
GCAGATAACGACTGGCTATTCA
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marrow contained 11 % leukemic blasts, all positive for CD7,
CD13, CD33, CD34, and HLA-DR. Cytogenetic analysis
indicated the presence of trisomy 8. The patient was diag-
nosed with MDS, classified into the refractory anemia with
excess blasts (RAEB-2), and had “Very high” risk according
to the criteria of revised international prognostic index (IPSS-
R) [12]. In January 2011, the case rapidly developed into
AML, and received hematopoietic stem cell transplantation
from a matched unrelated donor with reduced intensity con-
ditioning regimen.
Since the age of 16 years, he had been treated for
nontuberculous mycobacterial infection, cryptococcal menin-
gitis and recurrent cutaneous human papilloma virus infection.
For this reason, he was initially diagnosed with primary im-
munodeficiency. There was no family history of increased
susceptibility to infection, or onset of MDS/AML. Based on
our clinical findings and the family history, we suspected that
the patient might have sporadic MonoMAC syndrome.
Identification of a germline GATA-2 mutation
Sanger sequencing for GATA-2 cDNA revealed a 988 C > T
heterozygous mutation (Fig. 2a). We confirmed that the mu-
tation was germline because it involved the nail sample
(Fig. 2a). This mutation resulted in the generation of a prema-
ture stop codon at Arg330, located in the N-terminal zinc
finger domain (Fig. 2a). As GATA-2 DNA binding activity
is mediated through the C-terminal zinc finger domain [1], the
mutated GATA-2 is predicted to be defective in DNA binding.
To test the hypothesis, we overexpressed wild-type or mutated
(R330X) GATA-2 in K562 cells (Fig. 2b). Quantitative ChIP
analysis was conducted with anti-GATA-2 antibody at endog-
enous loci (GATA-2 −4.6, −3.5 and −2.4 kb), which were
selected fromGATA-2 ChIP-seq analysis based on K562 cells
[8]. As shown in Fig. 2c, GATA-2 chromatin occupancy was
obviously increased by overexpression of wild-type GATA-2.
However, although the antibody could recognize GATA-2
330X (Fig. 2b), the levels of GATA-2 chromatin occupancy
in GATA-2 R330X-overexpressing K562 cells were similar to
the control cells. Thus, we consider that the heterozygous
GATA-2 R330X mutation is a loss-of-function mutation.
Generation and characterization of BM-MSCs
We established BM-MSCs from BM mononuclear cells from
the patient, and used for the reference control for whole-
genome analysis. Immunophenotypic analysis confirmed that
the BM-MSCs expressed typical markers, i.e., CD29, CD44,
CD90, and CD105, but not CD14, CD34, and CD45 (Sup-
plementary Fig. 1a) [13]. Furthermore, the established BM-
MSCs had the capacity to differentiate into adipocytes and
osteoblasts (Supplementary Fig. 1b). Sanger sequencing also
confirmed that the cells harbored the identical GATA-2 muta-
tion (Fig. 2a).
Whole-genome sequencing identified mutations in EZH2,
HECW2, and GATA-1
To elucidate the secondary genetic changes associated with
the evolution to MDS/AML, we performed whole-genome
sequencing with DNA samples from nail, MonoMAC, MDS,
and BM-MSCs (Fig. 1). However, the data from the nail
sample were excluded from the analysis due to a low mapping
rate of the sequence on the human genome.
First, we focused on the MDS-specific genome deletion.
GATA-2 plays a crucial role in the proliferation of hematopoi-
etic stem cells (HSCs) [1, 14]. Thus, it is possible thatGATA-2
haploinsufficient HSCs could have a reduced proliferative
activity. Therefore, secondary deletions involving oncogenic
genes, such as a tumor suppressor gene, may promote the
evolution to MDS/AML. In support of this hypothesis, a
recent study revealed that a heterozygous 3-kb deletion, re-
moving exons 7–9 of TP53 gene, was associated with the
onset of therapy-related AML through whole-genome se-
quencing [15]. To identify the MDS-specific gene deletion,
we used several SV callers, including BreakDancer, Pindel,
and CNVnator, as described previously [16]. However, we
failed to identify the candidate genomic deletion that may
contribute to the evolution into MDS.
Our next strategy was to sort out the point mutations, using
the GATKUnified Genotyper [11]. They were observed in the
MDS sample, but not in MonoMAC or BM-MSCs. A total of
280 MDS-specific nonsynonymous single nucleotide variants








Fig. 1 Study design. Whole-
genome sequencing conducted
with MonoMAC, MDS and BM-
MSCs samples to identify MDS-
specific genome alterations.
Sanger sequence-based validation
analysis was conducted on all
samples, including a nail sample
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down based on the single nucleotide polymorphism (SNP)
database, the functional missense database and NCBI informa-
tion (http://www.ncbi.nlm.nih.gov; Table 2). Finally, we
identified three candidate mutations, namely EZH2 (Enhancer
of zeste homolog 2, Drosophila), HECW2 (HECT, C2 and
WW domain containing E3 ubiquitin protein ligase 2), and
GATA-1 (GATA-binding protein 1; Table 2, Fig. 3). Sanger
sequence-based validation analysis confirmed that all three
mutations were observed only in the MDS sample (Fig. 3).
As expected, the peak height of the mutated signal was lower
than that of the wild-type signal, presumably reflecting the















































































Fig. 2 Identification of a
germline heterozygous GATA-2
mutation. a Heterozygous
germline GATA-2 mutation was
confirmed with the nail, BM-
MSC, MonoMAC and MDS
samples: GATA-2 c. 988 C > T, p.
R330X. ZF, zinc finger.
Numbering relative to adenine in
the ATG start codon of GATA-2
(GenBank NM_001145661.1)
and the first methionine
(GenBank NP_116027.2) [3]. b
Western blot analysis to detect
wild-type andmutated GATA-2 in
K562 cells. Actin was used as a
loading control. GATA-2 R330X
was detected by the anti-GATA-2
antibody (H-116), as it recognizes
amino acid residues 120–235 of
human GATA-2. Asterisk, cross-
reactive band. c Quantitative
ChIP analysis to examine GATA-
2 occupancy in wild-type and
mutated GATA-2-overexpressing
K562 cells (n=3, mean±SD).
NECDIN promoter was included
as a negative control
Table 2 Point mutations identified in MDS sample
Functional missense database
Name Chr. Depth SIFT PolyPhen2 LJB_PhyloP LJB MutationTaster LJB_LRT AA Change
EZH2 7 49 0.06 0.926 0.9839 0.9995 1.0 E210K
HECW2 2 61 0.06 0.002 0.03258 0.005 0.0318 V701M
GATA-1 X 21 0 0.944 0.99824 0.9999 1.0 R293Q
Three mutations were not identified in SNP database (dbSNP130 and 1000G_ALL)
Chr chromosome, SIFT sorting intolerant from tolerant, PolyPhen2 polymorphism phenotyping v2, LJB_PhyloP pathogenicity score from dbNSFP,
LJB_MutationTaster pathogenicity probability score from dbNSFP, LJB_LRT pathogenicity probability score from dbNSFP, AA amino acid.
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EZH2 is a member of the Polycomb group, which is
involved in the maintenance of the transcriptional repressive
state of genes by trimethylation of histone H3 at lysine 27
[17]. It is well established that EZH2 loss-of-function muta-
tions are frequently identified in MDS [18]. Amino acid
position at 210 (Glu) is located at SWI3-ADA2-N-CoR-
TFIIIB (SANT) domain that has been shown to interact both
with histone tails and with other proteins [19]. Whereas gain-
of-function mutations of EZH2 have also been attributable to
pathogenesis of lymphoma, the mutations were observed at
the C-terminal catalytic SET domain (Y641 and Y677) [20].
Thus, we assume that the EZH2 E210K mutation could be
loss-of-function mutation. HECW2 is predicted to be ubiqui-
tin ligase that degrades ATR (ataxia-telangiectasia-mutated-
and-Rad3-related) kinase [21]. However, its role in hemato-
poiesis is unknown. Finally, GATA-1 is a member of the
GATA transcription factors promoting erythrocyte, megakar-
yocyte, mast cell, and eosinophil development [1]. Amino
acid position at 293 (Arg) is located in the C-terminal zinc
finger domain, which is important for the recognition of the
(A/T)GATA(A/G) motif, and to confer its transcriptional ac-
tivity [1]. Noticeably, a recent report suggests that defective
GATA-1 function results in the dyserythropoiesis, which is
characteristic of MDS [22]. Based on the functional missense
database, the mutations of both E210K on EZH2 and R293Q
on GATA-1 may have significant effect on their endogenous
functions (Table 2). In support of the hypothesis, mutation
frequencies for EZH2 (38.8 %) and GATA-1 (38.1 %) were
higher than HECW2 (24.6 %; Fig. 4). Thus, at least two
secondary mutations in EZH2 and GATA-1 may have con-
tributed to the early stage of clonal evolution into MDS in the
Fig. 3 Validation analysis for
MDS-specific point mutations.
Validation analysis of the MDS-
specific point mutations. Sanger
sequence conducted to validate
point mutations identified by
whole-genome sequencing. For
the HECW2 mutation, the
nucleotide substitution was
described as opposite strand (G >





















GATA-2 EZH2 GATA-1 HECW2
Fig. 4 Quantification of the mutation load for EZH2, GATA-1 and
HECW2. Percentage of the mutated reads per the total number of reads
(both wild-type and mutated) in MDS sample was calculated for GATA-2
(c. 988 C > T), EZH2 (c. 628 G > A), GATA-1 (c. 878 G > A) and
HECW2 (c. 2101 G > A)
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present case. Future investigations are needed to determine the
possible involvement of HECW2 mutation.
In conclusion, we conducted whole-genome sequencing
with samples from a patient with germline GATA-2 mutation
evolving immunodeficiency and MDS/AML. The new muta-
tions we identified in EZH2, HECW2 and GATA-1 appear to
be important secondary events leading to the development of
MDS/AML of this patient.
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